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-BRIEF COMMUNICATION
Epidemiology
Somatic mutations in benign breast disease tissue and risk of
subsequent invasive breast cancer
Thomas E. Rohan1, Christopher A. Miller2, Tiandao Li2, Yihong Wang3, Olivier Loudig4, Mindy Ginsberg1, Andrew Glass5 and
Elaine Mardis6
BACKGROUND: Insights into the molecular pathogenesis of breast cancer might come from molecular analysis of tissue from early
stages of the disease.
METHODS: We conducted a case–control study nested in a cohort of women who had biopsy-conﬁrmed benign breast disease
(BBD) diagnosed between 1971 and 2006 at Kaiser Permanente Northwest and who were followed to mid-2015 to ascertain
subsequent invasive breast cancer (IBC); cases (n= 218) were women with BBD who developed subsequent IBC and controls,
individually matched (1:1) to cases, were women with BBD who did not develop IBC in the same follow-up interval as that for the
corresponding case. Targeted sequence capture and sequencing were performed for 83 genes of importance in breast cancer.
RESULTS: There were no signiﬁcant case–control differences in mutation burden overall, for non-silent mutations, for individual
genes, or with respect either to the nature of the gene mutations or to mutational enrichment at the pathway level. For seven
subjects with DNA from the BBD and ipsilateral IBC, virtually no mutations were shared.
CONCLUSIONS: This study, the ﬁrst to use a targeted multi-gene sequencing approach on early breast cancer precursor lesions to
investigate the genomic basis of the disease, showed that somatic mutations detected in BBD tissue were not associated with
breast cancer risk.
British Journal of Cancer (2018) 118:1662–1664; https://doi.org/10.1038/s41416-018-0089-7
INTRODUCTION
One model of the natural history of breast cancer posits that it
develops as a result of the progression of breast tissue through
speciﬁc histological forms of benign breast disease (BBD) and then
carcinoma in situ before ultimately developing into invasive breast
cancer (IBC)1. Consistent with this, women with a history of BBD
have a two-fold increase in the risk of developing subsequent IBC1.
Predicting the behavior of BBD requires an understanding of its
underlying biology2. In this regard, insights into the molecular
pathogenesis of breast cancer will potentially come from analyses
conducted on tissue from early stages of the disease2,3. Almost
inevitably, for studies attempting to relate early molecular
changes to the likelihood of subsequent invasive cancer, this
necessitates the use of formalin-ﬁxed, parafﬁn-embedded (FFPE)
archival tissue, because it obviates the need for both prospective
collection of data and tissue and for subsequent long-term follow-
up to ascertain outcome.
In the prospective study reported here, we examined the
association between somatic mutations detected in BBD tissue
and risk of subsequent IBC.
MATERIALS AND METHODS
Study population
The study population has been described in detail elsewhere4. In
brief, the study was conducted in a cohort of 15,395 women
who had biopsy-conﬁrmed BBD diagnosed between 1971 and
2006 at Kaiser Permanente Northwest (KPNW). Subsequent IBC
occurrence (to mid-2015) was ascertained by linking records
from the BBD cohort to the KPNW Tumor Registry. Institutional
Review Board approval was obtained at all participating sites,
and because the data/specimens were not collected speciﬁcally
for this research project and did not contain a code derived from
individual personal information, the study was considered not to
meet the deﬁnition of human subject research as deﬁned by
45 CFR 46, 102(f).
Study design/sample size
We conducted a case–control study nested within the BBD cohort.
Cases were women with BBD who subsequently developed IBC.
Using risk-set sampling, one control was selected for each case
and was matched to the corresponding case on age at diagnosis
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of BBD (+/−1 year) (and implicitly, given the risk-set sampling, on
duration of follow-up); controls were sampled randomly from the
risk-sets with replacement. In addition to being alive and free of
IBC, each control was required not to have undergone a
mastectomy before the date of diagnosis of breast cancer for its
matched case. The study was restricted to those who had
adequate quantity and quality of DNA extracted from both the
lesion and from the adjacent normal tissue (see below) and
successful sequence generation. This led to the exclusion of
13 samples, leaving 218 case–control pairs.
Histopathology/clinical data
FFPE blocks of BBD tissue were retrieved from storage.
Haematoxylin and eosin-stained sections were prepared and were
reviewed and classiﬁed according to standard histological
criteria1,5,6. Speciﬁcally, the BBD lesions were classiﬁed into the
following categories: (1) nonproliferative disease, (2) proliferative
disease without atypia, and (3) proliferative disease with atypia
(atypical ductal hyperplasia, atypical lobular hyperplasia, or both).
Specimens were designated as having proliferative changes if they
contained any of the following: ductal hyperplasia, papilloma,
radial scar, or sclerosing adenosis. Cysts, aopcrine metaplasia,
ﬁbroadenoma without epithelial hyperplasia, or columnar cell
change were considered to be non-proliferative unless they
contained one of the listed proliferative lesions. Columnar cell
lesions and ﬂat epithelial atypia were also evaluated based on the
World Health Organization criteria6: columnar cell change and
hyperplasia were categorised as proliferative disease without
atypia, and ﬂat epithelial atypia was categorised as proliferative
disease with atypia. Data on clinical/epidemiologic factors were
extracted from medical records.
Targeted sequence capture and sequencing
DNA was extracted separately from the BBD lesions and from
adjacent normal tissue (the latter enabling putative germline
variants to be excluded). Sequencing libraries were made from
samples with as little as 8.1 ng of input DNA, although the mean
input amount was 70.1 ng. An 83-gene panel was designed to
target all the exons of genes (see Supplementary Table 1) that
were selected based on their known importance in breast
cancer, as demonstrated by the The Cancer Genome Atlas breast
cancer study and others. The use of this targeted sequence
capture approach and the sequencing were performed as
described previously7.
Data analysis
Somatic single-nucleotide variants (SNVs) and short indels were
detected using the Genome Modeling system8. Sequence data
were aligned to reference sequence build GRCh37-lite-build37
using bwa version 0.5.99 (parameters: −t= 4, −q= 5), then
merged and deduplicated using picard version 1.46. SNVs were
detected using the union of four callers: (1) samtools version
r98210 (params: mpileup -BuDs) intersected with Somatic Sniper10
version 1.0.2 (params: -F vcf -q 1 -Q 15) and processed through
false-positive ﬁlter v1 (params: --bam-readcount- version 0.4
--bam-readcount-min-base-quality 15 --min-mapping-quality 40
--min-somatic-score 40), (2) VarScan11 version 2.3.6 ﬁltered by
varscan-high-conﬁdence ﬁlter version v1 and processed through
false-positive ﬁlter v1 (params: --bam-readcount-version 0.4 --bam-
readcount-min-base-quality 15), (3) Strelka11 version 1.0.11
(params: isSkipDepthFilters= 0), and (4) Mutect version 1.1.4.
Indels were detected using the union of three callers: (1) GATK
somatic-indel version 533612, (2) VarScan version 2.3.6 ﬁltered by
varscan-high-conﬁdence- indel version v1, and (3) Strelka version
1.0.10 (params: isSkipDepthFilters= 0).
SNVs and indels were further ﬁltered by requiring 20× coverage,
removing artifacts found in a panel of 905 normal exomes,
removing sites that exceeded 0.1% frequency in the 1000
genomes or NHLBI exome sequencing projects, and then using
a Bayesian classiﬁer (https://github.com/genome/genome/blob/
master/lib/perl/Genome/Model/Tools/Validation/IdentifyOutliers.
pm) and retaining variants classiﬁed as somatic with a binomial
log-likelihood of at least 5.
Samples were screened for FFPE artifacts by ﬁrst identifying
mutations with appropriate dinucleotide mutation context
(CG > TG) ref: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC4912568/ and variant allele frequency (VAF) <10%. Eighteen
samples were identiﬁed with at least three such putative
artifacts, suggesting that these samples had been adversely
affected by damage due to formalin ﬁxation. Eighty four
mutations ﬂagged as artifacts in these samples were removed
from further consideration.
Copy number variant calling was attempted, but the density of
the probes in this targeted panel was insufﬁcient to enable
accurate inference.
All statistical tests were performed with R version 3.3.1.
RESULTS
We sequenced the protein-coding exons of 83 genes in DNA
extracted from tissue samples from 436 patients (218 pairs of
matched case/control BBD samples, as well as 218 pairs of
matched normal tissue samples). We detected 504 somatic
mutations in the cases and 497 in the controls (mean variant
coverage 90.4×) with no signiﬁcant difference in overall mutation
burden (via paired t-test, Supplementary Table 2a). Restricting the
comparison to non-silent mutations gave counts of 332 mutations
in the cases and 333 in the controls. No individual gene had
signiﬁcantly different numbers of mutations between the cases
and controls, whether considering all mutations or only non-silent
mutations (Fig. 1a). This was true whether considering putative
founding clone mutations (VAF > 25%) or all mutations (Fig. 1b).
One gene, KIT, was exclusively mutated in patients who
progressed to IBC but failed to reach statistical signiﬁcance after
multiple testing correction (paired t-test, p= 0.0302, False
Discovery Rate= 1). No substantial differences between cases
and controls were observed in the nature of mutations within
genes (i.e., PIK3CA(1047) vs other PIK3CA mutations). We also
examined mutational enrichment at the pathway level, using
ConsensusPathDB13 and, alternatively, by taking the nearest
neighbors of each gene in protein–protein interaction networks
obtained from Genemania14. No signiﬁcant pathway enrichment
was observed.
For seven subjects, we obtained tissue samples from the
subsequent ipsilateral IBC. We sequenced DNA from these
samples using the same targeted panel of genes described
above. In total, 28 mutations were observed, and none was shown
deﬁnitively to be shared between the BBD and IBC (Fig. 1b,
Supplementary Table 2b).
DISCUSSION
This is the ﬁrst study that has used a targeted multi-gene
sequencing approach on early breast cancer precursor lesions to
investigate the genomic basis of the disease. Though not
statistically signiﬁcant, the exclusivity of KIT mutations to lesions
that progressed to IBC is nonetheless deserving of further
investigation in a larger cohort. Overall, the null results may
reﬂect sample size limitations, the limited gene set and regions
analysed, and misclassiﬁcation of mutation status due to
impaired DNA quality. The fact that somatic mutations were
observed to be private between the BBD and IBC samples likely
arises from the fact that the BBD biopsies were both spatially
and temporally distinct from the IBC biopsies. In each case, we
clearly did not sample the population of cells that ultimately
gave rise to the tumour. Without a more comprehensive assay
Somatic mutations and breast cancer risk














(that includes all mutations and copy number alterations), we
cannot say whether the BBDs were completely independent
clonal expansions or whether they shared key founding
mutations that we did not detect (perhaps copy number events,
which are frequently observed as “early” events in tumour
evolution). In the latter case, the BBD biopsies would represent a
“dead end” tumour subclone that was ultimately outcompeted
by other tumour cells with additional mutations and increased
ﬁtness.
Despite the null results reported here, further investigation,
exploiting the vast archives of FFPE breast tumour tissue with
clinical outcome data using similar or even more detailed
approaches (e.g., exome/whole-genome sequencing) to those
employed here, is warranted. Such work has translational potential
given that identiﬁcation of DNA changes associated with
increased risk may allow early detection of women at risk for
breast cancer and may foster the development of new approaches
to the clinical management of women with BBD2,15.
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Variants with VAF > 25% All variants
Fig. 1 a, b Number of cases (right) and controls (left) with non-silent mutations in speciﬁc genes. Shown are all genes where at least ﬁve cases
had mutations. Genes were tested for signiﬁcant differences between cases and controls using paired t-test and are ordered by p-value—none
reached signiﬁcance after multiple testing correction. c Variant allele frequencies (VAFs) of all mutations found in paired BBD and IBC samples
from seven patients. Red highlights indicate mutations with non-zero VAFs in both samples (all had two or fewer supporting reads in one of
the samples)
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